NASDAQ:CNMD - CONMED Stock Price, News, & Analysis

CONMED trades on the NASDAQ under the ticker symbol "CNMD."

CONMED declared a quarterly dividend on Friday, November 9th. Investors of record on Friday, December 14th will be given a dividend of $0.20 per share on Monday, January 7th. This represents a $0.80 dividend on an annualized basis and a yield of 1.17%. The ex-dividend date of this dividend is Thursday, December 13th. View CONMED's Dividend History.

CONMED Co. (NASDAQ:CNMD) posted its quarterly earnings data on Thursday, November, 1st. The medical technology company reported $0.46 earnings per share for the quarter, beating the consensus estimate of $0.45 by $0.01. The medical technology company had revenue of $202.30 million for the quarter, compared to analyst estimates of $198.51 million. CONMED had a return on equity of 9.51% and a net margin of 8.56%. The business's revenue was up 6.4% compared to the same quarter last year. During the same period in the prior year, the company earned $0.42 earnings per share. View CONMED's Earnings History.

CONMED is scheduled to release their next quarterly earnings announcement on Wednesday, January 30th 2019. View Earnings Estimates for CONMED.

CONMED updated its FY18 earnings guidance on Thursday, November, 1st. The company provided earnings per share guidance of $2.15-2.20 for the period, compared to the Thomson Reuters consensus estimate of $2.17. CONMED also updated its FY 2018 guidance to $2.15-2.20 EPS.

3 equities research analysts have issued twelve-month price objectives for CONMED's shares. Their predictions range from $78.00 to $83.00. On average, they expect CONMED's stock price to reach $80.6667 in the next twelve months. This suggests a possible upside of 18.3% from the stock's current price. View Analyst Price Targets for CONMED.

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for CONMED in the last year. There are currently 2 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for CONMED.

Media headlines about CNMD stock have been trending somewhat positive recently, InfoTrie Sentiment Analysis reports. InfoTrie identifies negative and positive media coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. CONMED earned a news sentiment score of 1.7 on InfoTrie's scale. They also assigned news coverage about the medical technology company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an impact on the company's share price in the next several days.

Some companies that are related to CONMED include Masimo (MASI), LivaNova (LIVN), GETINGE AB/ADR (GNGBY), NxStage Medical (NXTM), AxoGen (AXGN), Natus Medical (BABY), Viewray (VRAY), Cutera (CUTR), Electrocore (ECOR), BioLife Solutions (BLFS), Rockwell Medical (RMTI), Semler Scientific (SMLR), Fonar (FONR), Second Sight Medical Products (EYES) and Zynex (ZYXI).

CONMED's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (14.34%), Dimensional Fund Advisors LP (6.24%), Capital Research Global Investors (6.11%), Victory Capital Management Inc. (2.71%), Fisher Asset Management LLC (2.01%) and Bank of New York Mellon Corp (1.50%). Company insiders that own CONMED stock include Charles Farkas, Curt R Hartman, Daniel Jonas, Dirk Kuyper, Heather L Cohen, Jo Ann Golden, Luke A Pomilio, Mark E Tryniski, Nathan Folkert, Peter K Shagory, Stanley W Peters III and Terence M Berge. View Institutional Ownership Trends for CONMED.

CNMD stock was sold by a variety of institutional investors in the last quarter, including Victory Capital Management Inc., Dimensional Fund Advisors LP, William Blair Investment Management LLC, Alliancebernstein L.P., Fisher Asset Management LLC, JPMorgan Chase & Co., JPMorgan Chase & Co. and Pendal Group Ltd. Company insiders that have sold CONMED company stock in the last year include Daniel Jonas, Jo Ann Golden, Luke A Pomilio, Nathan Folkert, Peter K Shagory, Stanley W Peters III and Terence M Berge. View Insider Buying and Selling for CONMED.

CNMD stock was bought by a variety of institutional investors in the last quarter, including BlackRock Inc., Capital Research Global Investors, O Shaughnessy Asset Management LLC, American Century Companies Inc., Los Angeles Capital Management & Equity Research Inc., Panagora Asset Management Inc., Strs Ohio and Assenagon Asset Management S.A.. Company insiders that have bought CONMED stock in the last two years include Charles Farkas, Curt R Hartman, Heather L Cohen and Mark E Tryniski. View Insider Buying and Selling for CONMED.

Shares of CNMD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of CNMD stock can currently be purchased for approximately $68.17.

CONMED has a market capitalization of $1.93 billion and generates $796.39 million in revenue each year. The medical technology company earns $55.48 million in net income (profit) each year or $1.89 on an earnings per share basis. CONMED employs 3,100 workers across the globe.

The official website for CONMED is http://www.conmed.com.

CONMED's mailing address is 525 FRENCH ROAD, UTICA NY, 13502. The medical technology company can be reached via phone at 315-797-8375.